The importance of antimicrobial resistance in hospital-acquired and ventilator-associated pneumonia

Current Anaesthesia and Critical Care

Volumn 16, Issue 4, 2005, Pages 209-219

  Kollef, Marin H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial resistance; Hospital acquired pneumonia; Practice guidelines; Risk factors; Ventilator associated pneumonia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TEICOPLANIN; TOBRAMYCIN; TRIMETHOPRIM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; BACTERIUM CULTURE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONVALESCENCE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEBRILE NEUTROPENIA; HEALTH CARE COST; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INTENSIVE CARE UNIT; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK FACTOR; SEPSIS; SYSTEMATIC REVIEW; TREATMENT FAILURE; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 33644657056     PISSN: 09537112     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cacc.2005.11.008     Document Type: Article

References (118)

1. R. McEachern G.D. Campbell Jr Hospital-acquired pneumonia: Epidemiology, etiology, and treatment Infect Dis Clin North Am 12 3 1998 761-779
2. M.J. Richards J.R. Edwards D.H. Culver R.P. Gaynes Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System Crit Care Med 27 5 1999 887-892
3. S.K. Fridkin Increasing prevalence of antimicrobial resistance in intensive care units Crit Care Med 29 4 Suppl 2001 N64-N68
4. J.P. Lynch 3rd Hospital-acquired pneumonia: Risk factors, microbiology, and treatment Chest 119 2 Suppl 2001 373S-384S
5. J. Chastre J.Y. Fagon Ventilator-associated pneumonia Am J Respir Crit Care Med 165 7 2002 867-903
6. D.E. Craven K.A. Steger Epidemiology of nosocomial pneumonia. New perspectives on an old disease Chest 108 2 Suppl 1995 1S-16S
7. R. Gaynes Health care-associated bloodstream infections: A change in thinking Ann Intern Med 137 10 2002 850-851
8. O.C. Tablan L.J. Anderson R. Besser C. Bridges R. Hajjeh CDC et. al. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee MMWR Recomm Rep 53 RR-3 2004 1-36
9. J.M. Mylotte Nursing home-acquired pneumonia Clin Infect Dis 35 10 2002 1205-1211
10. E. Hutt A.M. Kramer Evidence-based guidelines for management of nursing home-acquired pneumonia J Fam Pract 51 8 2002 709-716
11. American Thoracic Society, Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Am J Respir Crit Care Med 171 4 2005 388-416
12. J. Rello V. Ausina M. Ricart J. Castella G. Prats Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia Chest 104 4 1993 1230-1235
13. M.H. Kollef P. Silver D.M. Murphy E. Trovillion The effect of late-onset ventilator-associated pneumonia in determining patient mortality Chest 108 6 1995 1655-1662
14. A. Torres R. Aznar J.M. Gatell P. Jimenez J. Gonzalez A. Ferrer et. al. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients Am Rev Respir Dis 142 3 1990 523-528
15. L.A. Mandell J.G. Bartlett S.F. Dowell T.M. File Jr D.M. Musher C. Whitney et. al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults Clin Infect Dis 37 11 2003 1405-1433
16. J. Carlet A. Ben Ali A. Chalfine Epidemiology and control of antibiotic resistance in the intensive care unit Curr Opin Infect Dis 17 4 2004 309-316
17. J.L. Vincent D.J. Bihari P.M. Suter H.A. Bruining J. White M.H. Nicolas-Chanoin et. al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee JAMA 274 8 1995 639-644
18. H. Hanberger J.A. Garcia-Rodriguez M. Gobernado H. Goossens L.E. Nilsson M.J. Struelens Antibiotic susceptibility among aerobic Gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups JAMA 281 1 1999 67-71
19. R.N. Jones H.S. Sader M.L. Beach Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001) Int J Antimicrob Agents 22 6 2003 551-556
20. D.M. Livermore Bacterial resistance: Origins, epidemiology, and impact Clin Infect Dis 36 Suppl 1 2003 S11-S23
21. D.M. Shlaes D.N. Gerding J.F. John Jr W.A. Craig D.L. Bornstein R.A. Duncan et. al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals Clin Infect Dis 25 3 1997 584-599
22. M.M. Neuhauser R.A. Weinstein R. Rydman L.H. Danziger G. Karam J.P. Quinn Antibiotic resistance among Gram-negative bacilli in US intensive care units: Implications for fluoroquinolone use JAMA 289 7 2003 885-888
23. K. Sieradzki R.B. Roberts S.W. Haber A. Tomasz The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection N Engl J Med 340 7 1999 517-523
24. T.L. Smith M.L. Pearson K.R. Wilcox C. Cruz M.V. Lancaster B. Robinson-Dunn et. al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group N Engl J Med 340 7 1999 493-501
25. M. Van Looveren H. Goossens ARPAC Steering Group Antimicrobial resistance of Acinetobacter spp. in Europe Clin Microbiol Infect 10 8 2004 684-704
26. R. Canton T.M. Coque F. Baquero Multi-resistant Gram-negative bacilli: from epidemics to endemics Curr Opin Infect Dis 16 4 2003 315-325
27. P.K. Linden S. Kusne K. Coley P. Fontes D.J. Kramer D. Paterson Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa Clin Infect Dis 37 11 2003 e154-e160
28. D.M. Livermore M. Yuan Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe J Antimicrob Chemother 38 3 1996 409-424
29. G.L. Cartolano M. Cheron D. Benabid M. Leneveu A. Boisivon Association of Hospital Bacteriologists, Virologists and Hygiene Professionals Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals Clin Microbiol Infect 10 5 2004 448-451
30. M.H. Kollef V.J. Fraser Antibiotic resistance in the intensive care unit Ann Intern Med 134 4 2001 298-314
31. J.Y. Fagon J. Chastre Y. Domart J.L. Trouillet J. Pierre C. Darne et. al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques Am Rev Respir Dis 139 4 1989 877-884
32. J. Ortiz M.C. Vila G. Soriano J. Minana J. Gana B. Mirelis et. al. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients Hepatology 29 4 1999 1064-1069
33. S.L. Kaplan E.O. Mason Jr W.J. Barson E.R. Wald M. Arditi T.Q. Tan et. al. Three-year multicenter surveillance of systemic pneumococcal infections in children Pediatrics 102 3 Part 1 1998 538-545
34. M.B. Edmond J.F. Ober D.L. Weinbaum M.A. Pfaller T. Hwang M.D. Sanford et. al. Vancomycin-resistant Enterococcus faecium bacteremia: Risk factors for infection Clin Infect Dis 20 5 1995 1126-1133
35. R.N. Husni L.S. Goldstein A.C. Arroliga G.S. Hall C. Fatica J.K. Stoller et. al. Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients Chest 115 5 1999 1378-1382
36. J. Rello V. Ausina M. Ricart J. Castella G. Prats Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia Chest 104 4 1993 1230-1235
37. M.H. Kollef Ventilator-associated pneumonia. A multivariate analysis JAMA 270 16 1993 1965-1970
38. M.H. Kollef P. Silver D.M. Murphy E. Trovillion The effect of late-onset ventilator-associated pneumonia in determining patient mortality Chest 108 6 1995 1655-1662
39. J.L. Trouillet J. Chastre A. Vuagnat M.L. Joly-Guillou D. Combaux M.C. Dombret et. al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria Am J Respir Crit Care Med 157 2 1998 531-539
40. T.S. Naimi K.H. LeDell K. Como-Sabetti S.M. Borchardt D.J. Boxrud J. Etienne et. al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection JAMA 290 22 2003 2976-2984
41. N.M. Clark E. Hershberger M.J. Zervosc J.P. Lynch 3rd Antimicrobial resistance among Gram-positive organisms in the intensive care unit Curr Opin Crit Care 9 5 2003 403-412
42. J. Chastre M. Wolff J.Y. Fagon S. Chevret F. Thomas D. Wermert et. al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial JAMA 290 19 2003 2588-2598
43. P.J. Dennesen A.J. van der Ven A.G. Kessels G. Ramsay M.J. Bonten Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia Am J Respir Crit Care Med 163 6 2001 1371-1375
44. S. Nseir C. Di Pompeo S. Soubrier P. Delour H. Lenci M. Roussel-Delvallez et. al. First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit Crit Care Med 33 2 2005 283-289
45. E.H. Ibrahim G. Sherman S. Ward V.J. Fraser M.H. Kollef The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting Chest 118 1 2000 146-155
46. S. Harbarth K. Ferriere S. Hugonnet B. Ricou P. Suter D. Pittet Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care Arch Surg 137 12 2002 1353-1359 [discussion 1359]
47. F. Alvarez-Lerma Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group Intensive Care Med 22 5 1996 387-394
48. E.H. Ibrahim S. Ward G. Sherman R. Schaiff V.J. Fraser M.H. Kollef Experience with a clinical guideline for the treatment of ventilator-associated pneumonia Crit Care Med 29 6 2001 1109-1115
49. M.H. Kollef Inadequate antimicrobial treatment: An important determinant of outcome for hospitalized patients Clin Infect Dis 31 Suppl 4 2000 S131-S138
50. M.H. Kollef G. Sherman S. Ward V.J. Fraser Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients Chest 115 2 1999 462-474
51. M.H. Kollef S. Ward The influence of mini-BAL cultures on patient outcomes: Implications for the antibiotic management of ventilator-associated pneumonia Chest 113 2 1998 412-420
52. J. Rello M. Gallego D. Mariscal R. Sonora J. Valles The value of routine microbial investigation in ventilator-associated pneumonia Am J Respir Crit Care Med 156 1 1997 196-200
53. C.M. Luna P. Vujacich M.S. Niederman C. Vay C. Gherardi J. Matera et. al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia Chest 111 3 1997 676-685
54. J.F. Dhainaut P.F. Laterre S.P. LaRosa H. Levy G.E. Garber D. Heiselman et. al. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results Crit Care Med 31 9 2003 2291-2301
55. G.U. Meduri Diagnosis and differential diagnosis of ventilator-associated pneumonia Clin Chest Med 16 1 1995 61-93
56. S.K. Pingleton J.Y. Fagon K.V. Leeper Jr Patient selection for clinical investigation of ventilator-associated pneumonia. Criteria for evaluating diagnostic techniques Chest 102 5 Suppl 1 1992 553S-556S
57. C.P. Andrews J.J. Coalson J.D. Smith W.G. Johanson Jr Diagnosis of nosocomial bacterial pneumonia in acute, diffuse lung injury Chest 80 3 1981 254-258
58. J.Y. Fagon J. Chastre A.J. Hance M. Guiguet J.L. Trouillet Y. Domart et. al. Detection of nosocomial lung infection in ventilated patients. Use of a protected specimen brush and quantitative culture techniques in 147 patients Am Rev Respir Dis 138 1 1988 110-116
59. J.Y. Fagon J. Chastre A.J. Hance Y. Domart J.L. Trouillet C. Gibert Evaluation of clinical judgment in the identification and treatment of nosocomial pneumonia in ventilated patients Chest 103 2 1993 547-553
60. N. Fabregas S. Ewig A. Torres M. El-Ebiary J. Ramirez J.P. de La Bellacasa et. al. Clinical diagnosis of ventilator associated pneumonia revisited: Comparative validation using immediate post-mortem lung biopsies Thorax 54 10 1999 867-873
61. S.A. Rubin H.T. Winer-Muram J.V. Ellis Diagnostic imaging of pneumonia and its complications in the critically ill patient Clin Chest Med 16 1 1995 45-59
62. R.G. Wunderink L.S. Woldenberg J. Zeiss C.M. Day J. Ciemins D.A. Lacher The radiologic diagnosis of autopsy-proven ventilator-associated pneumonia Chest 101 2 1992 458-463
63. J.M. Sanchez-Nieto A. Torres F. Garcia-Cordoba M. El-Ebiary A. Carrillo J. Ruiz et. al. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: A pilot study Am J Respir Crit Care Med 157 2 1998 371-376 [Erratum in: Am J Respir Crit Care Med 1998;157(3 Part 1):1005]
64. M. Ruiz A. Torres S. Ewig M.A. Marcos A. Alcon R. Lledo et. al. Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: Evaluation of outcome Am J Respir Crit Care Med 162 1 2000 119-125
65. J. Sole Violan J.A. Fernandez A.B. Benitez J.A. Cardenosa Cendrero F. Rodriguez de Castro Impact of quantitative invasive diagnostic techniques in the management and outcome of mechanically ventilated patients with suspected pneumonia Crit Care Med 28 8 2000 2737-2741
66. J.Y. Fagon J. Chastre M. Wolff C. Gervais S. Parer-Aubas F. Stephan et. al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial Ann Intern Med 132 8 2000 621-630
67. A.F. Shorr J.H. Sherner W.L. Jackson M.H. Kollef Invasive approaches to the diagnosis of ventilator-associated pneumonia: A meta-analysis Crit Care Med 33 1 2005 46-53
68. J. Rello L. Vidaur A. Sandiumenge A. Rodriguez B. Gualis C. Boque et. al. De-escalation therapy in ventilator-associated pneumonia Crit Care Med 32 11 2004 2183-2190
69. G.A. Joiner D. Salisbury G.E. Bollin Utilizing quality assurance as a tool for reducing the risk of nosocomial ventilator-associated pneumonia Am J Med Qual 11 2 1996 100-103
70. S.I. Kelleghan C. Salemi S. Padilla M. McCord G. Mermilliod T. Canola et. al. An effective continuous quality improvement approach to the prevention of ventilator-associated pneumonia Am J Infect Control 21 6 1993 322-330
71. J.M. Boyce R.L. White E.Y. Spruill M. Wall Cost-effective application of the Centers for Disease Control Guideline for Prevention of Nosocomial Pneumonia Am J Infect Control 13 5 1985 228-232
72. R.P. Gaynes S. Solomon Improving hospital-acquired infection rates: The CDC experience Jt Comm J Qual Improv 22 7 1996 457-467
73. J.E. Zack T. Garrison E. Trovillion D. Clinkscale C.M. Coopersmith V.J. Fraser et. al. Effect of an education program aimed at reducing the occurrence of ventilator-associated pneumonia Crit Care Med 30 11 2002 2407-2412
74. H.M. Babcock J.E. Zack T. Garrison E. Trovillion M. Jones V.J. Fraser et. al. An educational intervention to reduce ventilator-associated pneumonia in an integrated health system: A comparison of effects Chest 125 6 2004 2224-2231
75. D.C. Classen S.L. Pestotnik R.S. Evans J.F. Lloyd J.P. Burke Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality JAMA 277 4 1997 301-306
76. R.S. Evans D.C. Classen S.L. Pestotnik H.P. Lundsgaarde J.P. Burke Improving empiric antibiotic selection using computer decision support Arch Intern Med 154 8 1994 878-884
77. S.L. Pestotnik D.C. Classen R.S. Evans J.P. Burke Implementing antibiotic practice guidelines through computer-assisted decision support: Clinical and financial outcomes Ann Intern Med 124 10 1996 884-890
78. R.S. Evans S.L. Pestotnik D.C. Classen T.P. Clemmer L.K. Weaver J.F. Orme Jr et. al. A computer-assisted management program for antibiotics and other antiinfective agents N Engl J Med 338 4 1998 232-238
79. T.C. Bailey D.J. Ritchie S.T. McMullin M. Kahn R.M. Reichley E. Casabar et. al. A randomized, prospective evaluation of an interventional program to discontinue intravenous antibiotics at two tertiary care teaching institutions Pharmacotherapy 17 2 1997 277-281
80. S.T. Micek S. Ward V.J. Fraser M.H. Kollef A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia Chest 125 5 2004 1791-1799
81. J.E. McGowan Jr D.N. Gerding Does antibiotic restriction prevent resistance? New Horiz 4 3 1996 370-376
82. R.P. Rifenburg J.A. Paladino S.C. Hanson J.A. Tuttle J.J. Schentag Benchmark analysis of strategies hospitals use to control antimicrobial expenditures Am J Health Syst Pharm 53 17 1996 2054-2062
83. M.W. Climo D.S. Israel E.S. Wong D. Williams P. Coudron S.M. Markowitz Hospital-wide restriction of clindamycin: Effect on the incidence of Clostridium difficile-associated diarrhea and cost Ann Intern Med 128 12 Part 1 1998 989-995
84. J. Quale D. Landman E. Atwood B. Kreiswirth B.M. Willey V. Ditore et. al. Experience with a hospital-wide outbreak of vancomycin-resistant enterococci Am J Infect Control 24 5 1996 372-379
85. P.P. Gleason W.N. Kapoor R.A. Stone J.R. Lave D.S. Obrosky R. Schulz et. al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia JAMA 278 1 1997 32-39
86. R.K. Ailani G. Agastya R.K. Ailani B.N. Mukunda R. Shekar Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia Arch Intern Med 159 3 1999 266-270
87. C. McNulty M. Logan I.P. Donald D. Ennis D. Taylor R.N. Baldwin et. al. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy J Antimicrob Chemother 40 5 1997 707-711
88. A.F. Shorr J.H. Sherner W.L. Jackson M.H. Kollef Invasive approaches to the diagnosis of ventilator-associated pneumonia: A meta-analysis Crit Care Med 33 1 2005 46-53
89. N. Singh P. Rogers C.W. Atwood M.M. Wagener V.L. Yu Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription Am J Respir Crit Care Med 162 2 Part 1 2000 505-511
90. M. Paul I. Benuri-Silbiger K. Soares-Weiser L. Leibovici Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: Systematic review and meta-analysis of randomised trials BMJ 328 7441 2004 668 [Erratum in: BMJ 2004;328(7444):884]
91. M. Paul K. Soares-Weiser L. Leibovici Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: Systematic review and meta-analysis BMJ 326 7399 2003 1111
92. S.T. Micek A.E. Lloyd D.J. Ritchie R.M. Reichley V.J. Fraser M.H. Kollef Pseudomonas aeruginosa bloodstream infection: Importance of appropriate initial antimicrobial treatment Antimicrob Agents Chemother 49 4 2005 1306-1311
93. M.S. Niederman Is "crop rotation" of antibiotics the solution to a "resistant" problem in the ICU? Am J Respir Crit Care Med 156 4 Part 1 1997 1029-1031
94. C.T. Bergstrom M. Lo M. Lipsitch Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals Proc Natl Acad Sci USA 101 36 2004 13285-13290
95. D. Gruson G. Hilbert F. Vargas R. Valentino C. Bebear A. Allery et. al. Rotation and restricted use of antibiotics in a medical intensive care unit. Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria Am J Respir Crit Care Med 162 3 Part 1 2000 837-843
96. D. Gruson G. Hilbert F. Vargas R. Valentino N. Bui S. Pereyre et. al. Strategy of antibiotic rotation: Long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia Crit Care Med 31 7 2003 1908-1914
97. D.P. Raymond S.J. Pelletier T.D. Crabtree T.G. Gleason L.L. Hamm T.L. Pruett et. al. Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit Crit Care Med 29 6 2001 1101-1108
98. M.G. Hughes H.L. Evans T.W. Chong R.L. Smith D.P. Raymond S.J. Pelletier et. al. Effect of an intensive care unit rotating empiric antibiotic schedule on the development of hospital-acquired infections on the non-intensive care unit ward Crit Care Med 32 1 2004 53-60
99. D.K. Warren H.A. Hill L.R. Merz M.H. Kollef M.K. Hayden V.J. Fraser et. al. Cycling empirical antimicrobial agents to prevent emergence of antimicrobial-resistant Gram-negative bacteria among intensive care unit patients Crit Care Med 32 12 2004 2450-2456
100. H.J. van Loon M.R. Vriens A.C. Fluit A. Troelstra C. van der Werken J. Verhoef et. al. Antibiotic rotation and development of Gram-negative antibiotic resistance Am J Respir Crit Care Med 171 5 2005 480-487
101. M.J. Bonten M.H. Kollef J.B. Hall Risk factors for ventilator-associated pneumonia: From epidemiology to patient management Clin Infect Dis 38 8 2004 1141-1149
102. L.M. Dunbar R.G. Wunderink M.P. Habib L.G. Smith A.M. Tennenberg M.M. Khashab et. al. High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm Clin Infect Dis 37 6 2003 752-760 [Erratum in: Clin Infect Dis 2003;37(8):1147]
103. S. Gibot A. Cravoisy B. Levy M.C. Bene G. Faure P.E. Bollaert Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia N Engl J Med 350 5 2004 451-458
104. S. Gibot M.N. Kolopp-Sarda M.C. Bene A. Cravoisy B. Levy G.C. Faure et. al. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis Ann Intern Med 141 1 2004 9-15 [Erratum in: Ann Intern Med 2005;142(7):592]
105. A.S. Benko D.M. Cappelletty J.A. Kruse M.J. Rybak Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected Gram-negative infections Antimicrob Agents Chemother 40 3 1996 691-695
106. E. Boselli D. Breilh F. Duflo M.C. Saux R. Debon D. Chassard et. al. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia Crit Care Med 31 8 2003 2102-2106
107. M. Wysocki F. Delatour F. Faurisson A. Rauss Y. Pean B. Misset et. al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: Prospective multicenter randomized study Antimicrob Agents Chemother 45 9 2001 2460-2467
108. J. Lipman S.C. Wallis C. Rickard Low plasma cefepime levels in critically ill septic patients: Pharmacokinetic modeling indicates improved troughs with revised dosing Antimicrob Agents Chemother 43 10 1999 2559-2561
109. R.D. Moore P.S. Lietman C.R. Smith Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration J Infect Dis 155 1 1987 93-99
110. J. Blaser B.B. Stone M.C. Groner S.H. Zinner Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance Antimicrob Agents Chemother 31 7 1987 1054-1060
111. G.A. Verpooten R.A. Giuliano L. Verbist G. Eestermans M.E. De Broe Once-daily dosing decreases renal accumulation of gentamicin and netilmicin Clin Pharmacol Ther 45 1 1989 22-27
112. J.K. Thomas A. Forrest S.M. Bhavnani J.M. Hyatt A. Cheng C.H. Ballow et. al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy Antimicrob Agents Chemother 42 3 1998 521-527
113. J.J. Schentag K.K. Gilliland J.A. Paladino What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 32 Suppl 1 2001 S39-S46
114. R.G. Wunderink J. Rello S.K. Cammarata R.V. Croos-Dabrera M.H. Kollef Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia Chest 124 5 2003 1789-1797
115. M.H. Kollef J. Rello S.K. Cammarata R.V. Croos-Dabrera R.G. Wunderink Clinical cure and survival in Gram-positive ventilator-associated pneumonia: Retrospective analysis of two double-blind studies comparing linezolid with vancomycin Intensive Care Med 30 3 2004 388-394
116. P.A. Moise A. Forrest S.M. Bhavnani M.C. Birmingham J.J. Schentag Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus Am J Health Syst Pharm 57 Suppl 2 2000 S4-S9 [Erratum in: Am J Health Syst Pharm 2001;58(1):78]
117. S.A. Shelburne D.M. Musher K. Hulten H. Ceasar M.Y. Lu I. Bhaila et. al. In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations Antimicrob Agents Chemother 48 10 2004 4016-4019
118. C. Lamer V. de Beco P. Soler S. Calvat J.Y. Fagon M.C. Dombret et. al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients Antimicrob Agents Chemother 37 2 1993 281-286